ICON Management
Management criteria checks 3/4
ICON's CEO is Barry Balfe, appointed in Oct 2025, has a tenure of less than a year. total yearly compensation is $3.29M, comprised of 25.9% salary and 74.1% bonuses, including company stock and options. directly owns 0.006% of the company’s shares, worth €686.84K. The average tenure of the management team and the board of directors is 3.8 years and 6.2 years respectively.
Key information
Barry Balfe
Chief executive officer
US$3.3m
Total compensation
| CEO salary percentage | 25.90% |
| CEO tenure | less than a year |
| CEO ownership | 0.006% |
| Management average tenure | 3.8yrs |
| Board average tenure | 6.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$27m |
| Mar 31 2026 | n/a | n/a | US$173m |
| Dec 31 2025 | US$3m | US$851k | US$214m |
Compensation vs Market: Barry's total compensation ($USD3.29M) is below average for companies of similar size in the German market ($USD6.13M).
Compensation vs Earnings: Insufficient data to compare Barry's compensation with company performance.
CEO
Barry Balfe (47 yo)
Mr. Barry Balfe serves as Chief Executive Officer and Director at ICON Public Limited Company since October 1, 2025. He served as President of ICON Pharma Solutions at ICON Public Limited Company since 202...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$3.29m | 0.0062% € 686.8k | |
| Founder & Independent Non-Executive Director | no data | US$320.00k | 0.0027% € 297.7k | |
| Chief Financial Officer | 1.9yrs | US$2.09m | 0.0076% € 840.1k | |
| Chief Commercial Officer | 1.7yrs | US$19.96m | no data | |
| Chief Accounting Officer | no data | no data | 0.00097% € 106.9k | |
| Chief Information Officer | no data | no data | no data | |
| Chief Administrative Officer | 16.8yrs | no data | no data | |
| Director of Corporate Communications | no data | no data | no data | |
| Vice President of Marketing | no data | no data | no data | |
| Chief Human Resources Officer | 10.2yrs | no data | no data | |
| President of Corporate Investments & Partnerships | 3.8yrs | no data | no data | |
| Senior Vice President of Global Clinical Pharmacology | 17.4yrs | no data | no data |
Experienced Management: IJF's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$3.29m | 0.0062% € 686.8k | |
| Founder & Independent Non-Executive Director | 16.7yrs | US$320.00k | 0.0027% € 297.7k | |
| Independent Director | 5.2yrs | US$353.00k | 0.0080% € 880.9k | |
| Independent Non-Executive Director | 8.9yrs | US$353.00k | 0.0049% € 544.6k | |
| Independent Non-Executive Chairman of the Board | 14.9yrs | US$710.00k | 0.027% € 2.9m | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Lead Independent Director | 9.9yrs | US$398.00k | 0.0050% € 550.1k | |
| Independent Non-Executive Director | 2.2yrs | US$248.00k | 0.0011% € 126.8k | |
| Independent Non-Executive Director | 7.2yrs | US$345.00k | 0.0046% € 502.7k | |
| Independent Non-Executive Director | less than a year | no data | no data |
Experienced Board: IJF's board of directors are considered experienced (6.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/11 02:52 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ICON Public Limited Company is covered by 32 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eric Coldwell | Baird |
| Douglas Tsao | Barclays |
| Luke Sergott | Barclays |